Crescent Biopharma (CBIO) Amortizatization of Intangibles (2019 - 2026)
Crescent Biopharma (CBIO) reported Amortizatization of Intangibles of $97000.0 for Q1 2026, up 2.11% on a QoQ basis from $95000.0 in Q4 2025.
Crescent Biopharma (CBIO) has 8 years of Amortizatization of Intangibles data on file, last reported at $97000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles changed N/A year-over-year to $97000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $309000.0 (up 77.54% YoY) and the FY2025 annual result came in at $212000.0, down 47.35% from the prior year.
- Amortizatization of Intangibles climbed to $97000.0 in Q1 2026 per CBIO's latest filing, from $95000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $227190.0 in Q3 2023 and bottomed at $23000.0 in Q2 2025.
- The 5-year median for Amortizatization of Intangibles is $193148.0 (2022), against an average of $166704.9.
- The widest annual swing landed in 2023, when Amortizatization of Intangibles advanced 10.21%; it then sank 86.79% in 2025.
- Tracing CBIO's Amortizatization of Intangibles over 5 years: stood at $213848.0 in 2022, then dropped by 12.33% to $187482.0 in 2023, then declined by 7.17% to $174048.0 in 2024, then plunged by 45.42% to $95000.0 in 2025, then increased by 2.11% to $97000.0 in 2026.
- Per Business Quant, the three latest CBIO Amortizatization of Intangibles figures stand at $97000.0 (Q1 2026), $95000.0 (Q4 2025), and $94000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | 97,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 97,000.00 |
| Mar 31, 2026 | 97,000.00 |
| Dec 31, 2025 | 95,000.00 |
| Dec 31, 2025 | 95,000.00 |
| Sep 30, 2025 | 94,000.00 |
| Sep 30, 2025 | 94,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Jun 30, 2024 | 174,048.00 |
| Jun 30, 2024 | 174,048.00 |
| Mar 31, 2024 | 169,571.00 |
| Mar 31, 2024 | 169,571.00 |
| Dec 31, 2023 | 187,482.00 |
| Dec 31, 2023 | 187,482.00 |
| Sep 30, 2023 | 227,190.00 |
| Sep 30, 2023 | 227,190.00 |
| Jun 30, 2023 | 222,447.00 |
| Jun 30, 2023 | 222,447.00 |
| Mar 31, 2023 | 219,119.00 |
| Mar 31, 2023 | 219,119.00 |
| Dec 31, 2022 | 213,848.00 |
| Dec 31, 2022 | 213,848.00 |
| Sep 30, 2022 | 208,684.00 |
| Sep 30, 2022 | 208,684.00 |
| Jun 30, 2022 | 203,665.00 |
| Jun 30, 2022 | 203,665.00 |
| Mar 31, 2022 | 198,814.00 |
| Mar 31, 2022 | 198,814.00 |
| Dec 31, 2021 | 194,078.00 |
| Dec 31, 2021 | 194,078.00 |
| Sep 30, 2021 | 189,440.00 |
| Sep 30, 2021 | 189,440.00 |
| Jun 30, 2021 | 184,935.00 |
| Jun 30, 2021 | 184,935.00 |
| Mar 31, 2021 | 180,586.00 |
| Mar 31, 2021 | 180,586.00 |
| Dec 31, 2020 | 176,341.00 |
| Dec 31, 2020 | 176,341.00 |
| Sep 30, 2020 | 172,091.00 |
| Sep 30, 2020 | 172,091.00 |
| Jun 30, 2020 | 168,151.00 |
| Jun 30, 2020 | 168,151.00 |
| Mar 31, 2020 | 164,262.00 |
| Mar 31, 2020 | 164,262.00 |
| Dec 31, 2019 | 160,469.00 |
| Dec 31, 2019 | 160,469.00 |
| Sep 30, 2019 | 156,756.00 |
| Sep 30, 2019 | 156,756.00 |
| Jun 30, 2019 | 153,157.00 |
| Jun 30, 2019 | 153,157.00 |
| Mar 31, 2019 | 149,686.00 |
| Mar 31, 2019 | 149,686.00 |